1、 ROBERTS D M,JONES R B,SMITH R M,et al.Rituximab-associated hypogammaglobulinemia: incidence,predictors and outcomes in patients with multi-system autoimmune disease[J]. J Autoimmun,2015(57):60-65. ROBERTS D M,JONES R B,SMITH R M,et al.Rituximab-associated hypogammaglobulinemia: incidence,predictors and outcomes in patients with multi-system autoimmune disease[J]. J Autoimmun,2015(57):60-65.
2、 GUO L,KAPUR R,ASLAM R,et al.CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia[J]. Blood,2016,127(6):735-738. GUO L,KAPUR R,ASLAM R,et al.CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia[J]. Blood,2016,127(6):735-738.
3、 LIU W,WU D,HU T,et al.Efficiency of treatment with rituximab in platelet transfusion refractoriness: a study of 7 cases[J]. Int J Clin Exp Med,2015,8(8):14080-14084. LIU W,WU D,HU T,et al.Efficiency of treatment with rituximab in platelet transfusion refractoriness: a study of 7 cases[J]. Int J Clin Exp Med,2015,8(8):14080-14084.
4、 SAILLER L.Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks[J]. Clin Rev Allergy Immunol,2008,34(1):103-110. SAILLER L.Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks[J]. Clin Rev Allergy Immunol,2008,34(1):103-110.
5、 PAI S C,LO S C,LIN T S,et al.Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases[J]. Transfusion,2010,50(11):2318-2327. PAI S C,LO S C,LIN T S,et al.Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases[J]. Transfusion,2010,50(11):2318-2327.
6、 WANG J,XIA W,DENG J,et al,Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness[J]. Transfus Med,2018,28(1):40-46. WANG J,XIA W,DENG J,et al,Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness[J]. Transfus Med,2018,28(1):40-46.
7、 CID J,MAGNANO L,ACOSTA M,et al.Rituximab,plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness[J]. Platelets,2015,26(2):190-194. CID J,MAGNANO L,ACOSTA M,et al.Rituximab,plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness[J]. Platelets,2015,26(2):190-194.
8、 SOLVES P,SANZ J,FREIRIA C,et al.Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation[J]. Ann Hematol,2018,97(1):161-167. SOLVES P,SANZ J,FREIRIA C,et al.Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation[J]. Ann Hematol,2018,97(1):161-167.
9、 王谦明,张晓辉.造血干细胞移植术后血小板输注无效的诊治[J]. 中华内科杂志,2015,54(3):232-234. 王谦明,张晓辉.造血干细胞移植术后血小板输注无效的诊治[J]. 中华内科杂志,2015,54(3):232-234.
10、 RADIA R,PAMPHILON D.Transfusion strategies in patients undergoing stem-cell transplantation[J]. Expert Rev Hematol,2011,4(2):213-220. RADIA R,PAMPHILON D.Transfusion strategies in patients undergoing stem-cell transplantation[J]. Expert Rev Hematol,2011,4(2):213-220.
11、 LI G,LIU F,MAO X,et a1.The investigation of platelet transfusion refractory in 69 malignant patients undergoing hematopoietic stem cell transplantation[J].Transfus Apher Set,2011,45(1):21-24. LI G,LIU F,MAO X,et a1.The investigation of platelet transfusion refractory in 69 malignant patients undergoing hematopoietic stem cell transplantation[J].Transfus Apher Set,2011,45(1):21-24.
12、 LUBAN N L,MCBRIDE E,FORD J C,et a1.Transfusion medicine problems and solutions for the pediatric hematologist/oncologist[J].Pediatr Blood Cancer,2012,58(7):1106-1111. LUBAN N L,MCBRIDE E,FORD J C,et a1.Transfusion medicine problems and solutions for the pediatric hematologist/oncologist[J].Pediatr Blood Cancer,2012,58(7):1106-1111.
